NCT02187705已完成不适用
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,688
- 主要终点
- Number of patients with adverse events
研究概览
简要总结
The aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with essential hypertension
- •Minimum age of 18 years
排除标准
- •Not applicable
研究组 & 干预措施
Patients with normotension at baseline
干预措施: Telmisartan tablets (Drug)
Patients with essential hypertension at baseline
干预措施: Telmisartan tablets (Drug)
Patients with isolated hypertension at baseline
干预措施: Telmisartan tablets (Drug)
结局指标
主要结局
Number of patients with adverse events
时间窗: Up to 14 days
Changes from baseline in blood pressure
时间窗: Up to 14 days
Evaluation was performed separately for three patient groups depending on their hypertension status at baseline (normotension, essential hypertension and isolated hypertension)
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in HospitalsHypertensionNCT02238262Boehringer Ingelheim2,318
已完成
不适用
Micardis®. Observational Study in Patients With Essential HypertensionHypertensionNCT02200094Boehringer Ingelheim4,532
已完成
不适用
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential HypertensionHypertensionNCT02176850Boehringer Ingelheim19,870
已完成
不适用
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With HypertensionHypertensionNCT02242838Boehringer Ingelheim6,336
已完成
不适用
Nice Morning- Safety and Efficacy Observational Study of Telmisartan in Hypertensive Patients in MulticentersHypertensionNCT00615108Boehringer Ingelheim3,148